The record

LegislationLegislation· Oct 2026
HR 8205 Passed both chambers

Sponsored by Mike Quigley (D)

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Extends federal funding for ALS research and drug development programs through 2031.

Tradeoff

Reauthorizes grants for investigational ALS therapies and expands FDA oversight of safety data. No offsetting cuts or new revenue identified in the bill.

What's in it

See official bill text

Passed the House by on July 22, 2026. Passed the Senate by on September 28, 2026.

  1. House

    Introduced

    (Apr 6, 2026)

  2. House

    Committee on Energy and Commerce(Apr 6, 2026)

  3. House

    The Committee on Energy and Commerce voted to send it to the floor

    Reported 46 - 0(May 21, 2026)

    Committee report H. Rept. 119-733.

  4. House

    Passage of the bill

    Passed by (Jul 22, 2026)

    No individual votes were recorded.

  5. Senate

    Received from the House

    Received(Jul 23, 2026)

  6. Senate

    Passage of the bill

    Passed by (Sep 28, 2026)

    No individual votes were recorded.